Genezen and Optieum Biotechnologies Partner to Support cGMP Manufacturing of Groundbreaking CAR-T Therapy for Glioblastoma

Expanding Access to CGTs Through Innovative Payment Models: Joe DePinto, MBA

Innovative financing and reimbursement models can improve access to cell and gene therapies, addressing cost barriers and improving patient outcomes, said Joe DePinto, MBA, of McKesson.

Astraveus Enters Strategic Partnership with NecstGen to evaluate Lakhesys Benchtop Cell FactoryTM for CAR-T therapy manufacturing – Optimum Strategic CommunicationsLink to: Weekly roundup: Another busy week in biopharmaLink to: Alchemab Therapeutics signs

Agreement with Netherlands Center for the Clinical Advancement of Stem Cell and Gene Therapies (NecstGen) for the manufacturing of CAR-T therapies using Lakhesys Benchtop Cell FactoryTM Partnership to demonstrate the ability of Astraveus’ technology to deliver reduced costs and increased efficiency in CAR-T manufacturing Paris, France, 6 May 2025 – Astraveus SAS (“Astraveus” or the […]

Genezen and Optieum Biotechnologies Partner to Support cGMP Manufacturing of Groundbreaking CAR-T Therapy for Glioblastoma

Collaboration supports manufacture of the OPTF01 product to Drive Next-Generation Chimeric Antigen Receptor T Cell (CAR-T) Development INDIANAPOLIS and EHIME, Japan, May 5, 2025 /PRNewswire/ — Genezen, a leading viral vector Contract Development and Manufacturing Organization (CDMO), and Optieum Biotechnologies, Inc. (Optieum), a preclinical stage company dedicated to the discovery and development of innovative CAR-T cell therapies, […]